HGH peptides are short chains of amino acids that stimulate your pituitary gland to produce more of its own growth hormone. Unlike synthetic growth hormone injections, which replace your body’s natural production with an external source, these peptides work by signaling your brain to ramp up the growth hormone it already makes. They’ve gained popularity in anti-aging, fitness, and body composition circles, but they come with real biological tradeoffs and a complicated regulatory landscape.
How HGH Peptides Work
Your pituitary gland releases growth hormone in pulses throughout the day, regulated by two opposing signals from the brain: one that says “release” and one that says “hold.” HGH peptides tip that balance toward release through two distinct pathways. Some mimic the “release” signal directly, amplifying the message that tells the pituitary to secrete growth hormone. Others work by dampening the “hold” signal, effectively removing the brakes on secretion. When both types are combined, they produce a synergistic effect that’s greater than either one alone, which is why many peptide protocols pair them together.
Because these peptides enhance your body’s own pulsatile release pattern rather than flooding the system with a flat dose of external hormone, proponents argue they carry a lower risk of the extreme side effects associated with high-dose synthetic growth hormone. That claim has some physiological logic, but it doesn’t mean peptides are without consequences.
The Two Main Categories
HGH peptides fall into two functional groups based on which receptor pathway they activate. Understanding this distinction matters because it explains why certain peptides are often stacked together.
Growth Hormone Releasing Hormone Analogs
These peptides mimic the natural “release” signal your hypothalamus sends to the pituitary. Sermorelin is the most well-known example, and it was one of the first peptides used clinically to stimulate growth hormone. CJC-1295 is a modified version designed to last longer in the body, allowing for less frequent dosing. Tesamorelin is the only peptide in this category with full FDA approval, specifically for reducing excess abdominal fat in people with HIV-related lipodystrophy. In clinical trials, tesamorelin reduced deep abdominal fat by about 34 square centimeters over six months compared to a slight increase in the placebo group.
Growth Hormone Releasing Peptides
These peptides work through a completely different receptor. Rather than mimicking the brain’s release signal, they activate receptors related to ghrelin, the hunger hormone produced in your stomach. The effect is similar (more growth hormone gets released) but the mechanism is distinct, which is why combining one from each category produces a stronger response than doubling the dose of either alone. Ipamorelin is the most popular in this category because it triggers growth hormone release with relatively little effect on other hormones like cortisol. GHRP-6 is an older peptide in this class that tends to cause more appetite stimulation.
Common Peptide Combinations
CJC-1295 paired with Ipamorelin is the most widely used combination in peptide therapy clinics. The logic is straightforward: CJC-1295 amplifies the release signal while Ipamorelin removes the inhibitory brake, and together they produce a stronger, more sustained pulse of growth hormone. This combination is typically taken in smaller doses over a five-day cycle. Sermorelin, by comparison, usually requires seven days of dosing to achieve similar effects and tends to increase appetite more noticeably.
The choice between protocols often comes down to individual response. Some people tolerate one peptide better than another, and the hunger side effect from certain combinations can be either a benefit or a drawback depending on whether someone is trying to gain or lose weight.
Effects on Blood Sugar and Insulin
Growth hormone is what’s known as a counterregulatory hormone to insulin, meaning it pushes blood sugar in the opposite direction. When growth hormone levels rise, your liver produces more glucose while your fat and muscle tissue become less responsive to insulin. This is a well-established biological effect, not a rare side effect.
Studies on growth hormone therapy show that fasting glucose and insulin levels typically rise during the first few months of treatment, particularly at higher doses. In the tesamorelin trials, fasting glucose increased by about 9 mg/dL in the first two weeks, though this difference faded by six months. At lower doses, most research shows insulin sensitivity stays relatively unchanged over the long term. Two studies even found that low-dose growth hormone improved insulin sensitivity in people who were both growth hormone deficient and obese.
The practical takeaway: if you already have impaired blood sugar control or are prediabetic, raising growth hormone levels through any method adds metabolic stress your body may not handle well. This effect scales with dose, so higher or more frequent peptide use carries more risk.
Pituitary Response Over Time
One concern with long-term peptide use is whether the pituitary gland becomes desensitized, essentially stops responding as strongly to the signal. Research on hexarelin, a growth hormone releasing peptide, directly tested this. After just seven days of treatment, the pituitary’s peak growth hormone response to the peptide dropped by roughly half, falling from about 71 to 34 mU/L. That reduced response then held steady for the remaining six months of the study.
The interesting finding was that despite this blunted hormonal response, growth velocity in the study subjects still increased. The pituitary didn’t shut down entirely. It adapted to a new, lower level of responsiveness, but that level still produced enough additional growth hormone to have a measurable biological effect. This is meaningfully different from what happens with exogenous growth hormone injections, where your pituitary can significantly reduce its own production because external hormone is already present.
Still, the partial desensitization is real and worth understanding. It’s one reason many peptide protocols include cycling periods, with scheduled breaks to allow receptor sensitivity to recover.
Regulatory Status in the United States
The regulatory situation for HGH peptides is in flux and more restrictive than many people realize. Tesamorelin is the only growth hormone peptide with full FDA approval, and its approved use is narrow. Most other peptides people encounter, including Ipamorelin, CJC-1295, and Sermorelin, have been available through compounding pharmacies rather than as FDA-approved drugs.
The FDA has been tightening its oversight of compounded peptides. BPC-157, a popular peptide used for injury recovery, is currently listed in the FDA’s Category 2 for bulk drug substances, meaning the agency considers it to raise significant safety risks for compounding. Ipamorelin’s status has been particularly unstable. It was removed from the FDA’s Category 2 list after nominations were withdrawn, but the agency announced plans to consult its advisory committee about whether ipamorelin should be added to the approved compounding list.
What this means practically is that access to many peptides through legitimate compounding pharmacies has become uncertain. Peptides purchased from research chemical suppliers or gray-market sources carry additional risks: no guarantee of purity, accurate dosing, or sterility. The gap between what’s available in a clinical setting and what’s sold online is significant, and it’s widening as regulatory pressure increases.
Who Uses HGH Peptides and Why
The most common reasons people seek out peptide therapy include improving body composition (less fat, more lean mass), recovering from injuries faster, improving sleep quality, and slowing age-related decline in growth hormone production. Growth hormone output drops steadily after your 20s, declining roughly 14% per decade, and peptides are marketed as a way to restore more youthful levels.
The clinical evidence is strongest for body composition changes. Tesamorelin’s ability to reduce visceral fat is well-documented, and the mechanism applies broadly: growth hormone mobilizes fat from storage and shifts metabolism toward using fat for fuel. The evidence for anti-aging benefits, cognitive improvements, and injury healing is weaker and largely based on animal studies or small trials.
Side effects beyond blood sugar changes include water retention, joint stiffness, tingling or numbness in the hands, and increased hunger (especially with GHRP-class peptides). These effects are generally dose-dependent and tend to appear within the first few weeks of use. Most are mild enough that people continue therapy, but they’re signals that growth hormone levels are elevated and the body is adjusting.